OrbiMed Advisors Boosts Stake with $12.5M Purchase in Recent Offering, Now Owns 16%

summarizeSummary

OrbiMed Advisors updated its beneficial ownership to 16% of Prelude Therapeutics, having purchased approximately $12.5 million in common stock during the company's recent underwritten public offering.

check_boxKey Events

• Significant Investment in Offering

  OrbiMed Advisors and its affiliated entities purchased 2,815,315 shares of common stock for approximately $12.5 million in Prelude Therapeutics' underwritten public offering completed on April 21, 2026.

• Updated Beneficial Ownership

  Following the offering, OrbiMed Advisors LLC now beneficially owns an aggregate of 12,935,071 shares, representing 16% of the company's outstanding common stock.

• Institutional Confidence

  The substantial purchase by OrbiMed, a major institutional investor with board representation, demonstrates continued confidence in Prelude Therapeutics, despite the dilutive impact of the offering.

• Context of Recent Capital Raise

  This filing provides further detail on the participation in the $90.0 million underwritten offering, which was previously announced on April 20, 2026, and follows a similar purchase by Baker Bros. Advisors.

auto_awesomeAnalysis

This Schedule 13D/A filing confirms that OrbiMed Advisors, a significant institutional investor with a representative on Prelude Therapeutics' Board of Directors, increased its absolute shareholdings by purchasing approximately $12.5 million worth of common stock in the company's recent underwritten public offering. While the overall percentage ownership of OrbiMed decreased due to the dilutive nature of the offering, their substantial investment signals strong confidence in the company's future, especially coming shortly after positive preclinical data for PRT13722 and the appointment of a new Chief Medical Officer. This participation by a major investor helps to validate the offering and provides a positive signal amidst the dilution.